Merck & Co. 10Q 2023 Q1 Quarterly report | MRK Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Bad

New words: abstention, ADT, advice, Advocate, allogenic, androgen, answered, Australian, Baltimore, belzutifan, biomarker, blinded, bomedemstat, boundary, BRCAm, bundling, citing, CJEU, cm, CMV, coformulation, conclusion, convened, Council, counterclaiming, Crohn, crossed, curiam, customary, deferred, demethylase, deprivation, diagnostic, discrete, enfortumab, environment, equivalent, escalation, estoppel, expression, genetic, HCI, hematopoietic, Hong, hosted, IIIB, Imago, immunotherapy, inclusion, inflammation, intolerant, invited, involuntary, JHU, Kelun, Kong, Labor, letermovir, ligand, MAA, Macau, mainland, marrow, Maryland, Mayor, mCRPC, monoclonal, monopoly, myeloproliferative, Natco, noninfringement, numerically, OADC, ODAC, overhead, parasiticide, partnered, perioperative, permanent, pet, PMBCL, polycythemia, population, preclinical, proficient, promissory, proposed, pursuit, reach, reached, relapsed, relief, resale, reserved, retailer, retain, retained, satisfactory, scheme, Seagen, software, solution, stem, supracompetitive, Switzerland, tablet, thrombocythemia, transplant, trebled, ulcerative, unspecified, upgraded, vedotin, vera, vibostolimab, volume, voluntarily, von, waiting, Welireg

Removed: accelerating, Acceleron, acetate, adapt, adapted, age, alendronate, alleviate, analogy, antibacterial, anticipate, arbitration, arising, Artiva, Assistant, assumed, atypical, back, bacterial, banking, BARDA, benchmark, beneficial, Biomedical, Breakthrough, build, burden, California, capacity, causation, ceftolozane, Certificate, clarifying, classified, CLEAR, combine, compliance, concentrate, Conditional, continuation, continuity, converted, convertible, County, curative, decided, degree, deny, Department, depend, dermatology, designation, difficult, digital, diluted, discontinue, discontinued, discover, distancing, distributed, diversified, DMC, drove, EC, economy, effectively, enablement, energy, enrolled, enrollment, ensuring, establish, evidence, evolving, examination, exceeded, expand, expedite, ezetimibe, facilitate, feedback, femur, fiscal, Fosamax, Fracture, fuel, geopolitical, German, germline, globe, grant, granting, half, heighten, Historically, hospitalized, humanitarian, hyperinflationary, IA, imposed, incorrectly, indemnify, initiating, instability, instance, intend, Interbank, intestine, invaded, invasion, investigating, IRS, issuance, issue, Johnson, jury, Kingdom, Labour, lesser, LIBOR, lira, London, longer, Los, magistrate, make, mandatory, manner, meaningful, model, modification, move, nephrectomy, noncontrolling, obligor, obtained, Offered, older, OlympiA, OncoImmune, optional, pain, persistent, person, pervasive, phased, plant, platform, pneumonia, pneumoniae, Portugal, precaution, predominately, preempted, preemption, presently, professional, proprietary, prospective, qualify, radiation, radically, rationalization, recall, refer, regional, remanding, reside, resolved, respiratory, resultant, resupply, retrospective, reversing, Russia, screening, Secretary, selected, social, sodium, Southern, span, statute, stayed, sterility, stop, stronger, submit, subsequent, substantial, supplied, suspected, suspended, sustained, Sweden, systemic, tazobactam, technical, temporarily, timeline, toll, transparency, travel, treat, Turkey, Turkish, Ukraine, unfavorably, unrecognized, updated, variable, vast, viable, viral, war, warn, warning, women, working, Zerbaxa



Date: May 5, 2023	/s/ Robert M. Davis
	Name: Title:	ROBERT M. DAVIS Chairman, Chief Executive Officer and President

Merck & Co. (MRK) 10-Q2023 Q1 Quarterly report

Content analysis